Department of Human Anatomy and Cell Science, Max Rady College of Medicine, University of Manitoba, Winnipeg, MB, Canada.
Department of Pharmacy, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Cell Mol Life Sci. 2023 Sep 26;80(10):304. doi: 10.1007/s00018-023-04956-9.
Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease. There is no cure currently. The discovery that mutations in the gene SOD1 are a cause of ALS marks a breakthrough in the search for effective treatments for ALS. SOD1 is an antioxidant that is highly expressed in motor neurons. Human SOD1 is prone to aberrant modifications. Familial ALS-linked SOD1 variants are particularly susceptible to aberrant modifications. Once modified, SOD1 undergoes conformational changes and becomes misfolded. This study aims to determine the effect of selective removal of misfolded SOD1 on the pathogenesis of ALS.
Based on the chaperone-mediated protein degradation pathway, we designed a fusion peptide named CT4 and tested its efficiency in knocking down intracellularly misfolded SOD1 and its efficacy in modifying the pathogenesis of ALS.
Expression of the plasmid carrying the CT4 sequence in human HEK cells resulted in robust removal of misfolded SOD1 induced by serum deprivation. Co-transfection of the CT4 and the G93A-hSOD1 plasmids at various ratios demonstrated a dose-dependent knockdown efficiency on G93A-hSOD1, which could be further increased when misfolding of SOD1 was enhanced by serum deprivation. Application of the full-length CT4 peptide to primary cultures of neurons expressing the G93A variant of human SOD1 revealed a time course of the degradation of misfolded SOD1; misfolded SOD1 started to decrease by 2 h after the application of CT4 and disappeared by 7 h. Intravenous administration of the CT4 peptide at 10 mg/kg to the G93A-hSOD1 reduced human SOD1 in spinal cord tissue by 68% in 24 h and 54% in 48 h in presymptomatic ALS mice. Intraperitoneal administration of the CT4 peptide starting from 60 days of age significantly delayed the onset of ALS and prolonged the lifespan of the G93A-hSOD1 mice.
The CT4 peptide directs the degradation of misfolded SOD1 in high efficiency and specificity. Selective removal of misfolded SOD1 significantly delays the onset of ALS, demonstrating that misfolded SOD1 is the toxic form of SOD1 that causes motor neuron death. The study proves that selective removal of misfolded SOD1 is a promising treatment for ALS.
肌萎缩侧索硬化症(ALS)是一种毁灭性的神经退行性疾病。目前尚无治愈方法。发现 SOD1 基因突变是 ALS 有效治疗方法的突破。SOD1 是一种在运动神经元中高度表达的抗氧化剂。人类 SOD1 容易发生异常修饰。家族性 ALS 相关 SOD1 变体特别容易发生异常修饰。一旦修饰,SOD1 就会发生构象变化并错误折叠。本研究旨在确定选择性去除错误折叠的 SOD1 对 ALS 发病机制的影响。
基于伴侣介导的蛋白质降解途径,我们设计了一种名为 CT4 的融合肽,并测试了其在敲低细胞内错误折叠的 SOD1 中的效率及其在修饰 ALS 发病机制中的功效。
在人 HEK 细胞中表达携带 CT4 序列的质粒导致由血清剥夺诱导的错误折叠的 SOD1 大量去除。在不同比例下共转染 CT4 和 G93A-hSOD1 质粒显示出对 G93A-hSOD1 的剂量依赖性敲低效率,当 SOD1 错误折叠通过血清剥夺增强时,该效率可进一步提高。将全长 CT4 肽应用于表达人类 SOD1 G93A 变体的原代神经元培养物中,揭示了错误折叠的 SOD1 降解的时间过程;CT4 应用 2 小时后,错误折叠的 SOD1 开始减少,7 小时后消失。在症状前 ALS 小鼠中,静脉内给予 10mg/kg 的 CT4 肽可在 24 小时内将脊髓组织中的人 SOD1 降低 68%,在 48 小时内降低 54%。从 60 天龄开始腹腔内给予 CT4 肽可显著延迟 ALS 的发作并延长 G93A-hSOD1 小鼠的寿命。
CT4 肽以高效和特异性引导错误折叠的 SOD1 降解。选择性去除错误折叠的 SOD1 可显著延迟 ALS 的发作,表明错误折叠的 SOD1 是导致运动神经元死亡的 SOD1 的有毒形式。该研究证明选择性去除错误折叠的 SOD1 是治疗 ALS 的一种有前途的方法。